Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
DOXORUBICIN HYDROCHLORIDE
Teva Pharma B.V.
DOXORUBICIN HYDROCHLORIDE
50 Milligram
Pdr/Conc/Soln for Infus
Product subject to prescription which may not be renewed (A)
Withdrawn
2013-11-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT DEBDOX 50mg powder for concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 vial contains 50 mg of doxorubicin hydrochloride (to be reconstituted with 25 ml) After reconstitution each ml contains 2 mg of doxorubicin hydrochloride. Excipients For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for concentrate for solution for infusion Red-orange, sterile powder 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Breast cancer - Neoadjuvant and adjuvant therapy of osteosarcoma - Advanced soft-tissue sarcoma in adults - Small-cell lung cancer (SCLC) - Hodgkin’s lymphoma - Highly malignant non-Hodgkin’s lymphoma - Induction and consolidation therapy in acute lymphatic leukaemia - Acute myeloblastic leukaemia - Advanced multiple myeloma - Advanced or recurrent endometrial carcinoma - Advanced or relapsed papillary/follicular thyroid cancer - Anaplastic thyroid cancer - Systemic treatment of local advanced or metastasized bladder carcinoma - Intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection - Recurrent ovarian carcinoma - Wilms’ tumour (in stage II in highly malignant variants, all advanced stages [III – IV]) - Advanced neuroblastoma - Ewing´s sarcoma Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DEBDOX should be administered only under the supervision of a qualified physician experienced in cytotoxic therapy. Also, patients must be carefully and frequently monitored during the treatment. Due to the risk of an often lethal cardiomyopathy, the risks and benefits to the individual patient should be weighted before each application. Prior to start Olvassa el a teljes dokumentumot